The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Singer B.

Krieger S.

Amezcua L.

Margolin D.H.

Kasten L.

Hartung H.-P.

Ustojchivaja effektivnost' alemtuzumaba u patsientov s vysokoaktivnym remittirujuschim rassejannym sklerozom, kotorye imeli neoptimal'nyj otvet na predshestvujuschuju terapiju: dannye 3-letnego nabljudenija v ramkah issledovanija CARE-MS II (Durable Efficacy of Alemtuzumab In Patients with highly active Relapsing-Remitting Multiple Sclerosis who had An Inadequate Response to Prior Therapy: CARE-MS II 3-year data)

Authors:

Boĭko A.N., Singer B., Krieger S., Amezcua L., Margolin D.H., Kasten L., Hartung H.-P.

More about the authors

Views: 278

Downloaded: 3


To cite this article:

Boĭko AN, Singer B, Krieger S, Amezcua L, Margolin DH, Kasten L, Hartung H-P. Ustojchivaja effektivnost' alemtuzumaba u patsientov s vysokoaktivnym remittirujuschim rassejannym sklerozom, kotorye imeli neoptimal'nyj otvet na predshestvujuschuju terapiju: dannye 3-letnego nabljudenija v ramkah issledovanija CARE-MS II (Durable Efficacy of Alemtuzumab In Patients with highly active Relapsing-Remitting Multiple Sclerosis who had An Inadequate Response to Prior Therapy: CARE-MS II 3-year data). S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(8‑2):53‑54. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.